hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06349928, orgStudyIdInfo id: MASF_Dancers01, briefTitle: "The Show Must go on" : The Experience of Injuries Among Dancers: Fears, Thoughts, and Beliefs. A Qualitative Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-30, completionDateStruct date: 2025-04-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: University of Siena, class: OTHER, descriptionModule briefSummary: This qualitative, cross-sectional study aims at describing the experience of Italian dancers with injury.Dancers face a high risk of sustaining one or more injuries during their career (87-94%), which may lead to physical, psychological, and socioeconomic consequences affecting dancer's lives and careers both short and long-term.Dancers report fearing injury and its consequences and believing in the existence of a stigma around injury and injured colleagues; many of them also try to self-manage pain and delay reporting injuries to healthcare professionals, possibly making its outcomes worse.This study will collect data from dancers via focus groups and individual interviews, investigating dancers' experiences, thoughts, and beliefs about injury. Records from the interviews will be transcribed ad verbatim and analyzed using the framework method to synthetize the data and highlight the most meaningful content.Understanding dancers' thoughts and behaviors regarding past or possible future injuries may be beneficial in improving treatment efficacy and designing adequate education and prevention strategies. It may also help raise awareness of dancers' complex and unique needs, and the importance of having accessible, specialized professionals around dance companies and schools., conditionsModule conditions: Injuries, conditions: Dancing, conditions: Injury;Sports, conditions: Stress, Psychological, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Focus group or interview, outcomesModule primaryOutcomes measure: Experience and perception of injury amongst dancers, secondaryOutcomes measure: Understanding of injury prevention and pain management amongst dancers, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349915, orgStudyIdInfo id: 2023-15217, briefTitle: A Pilot Evaluation of a Digital Peer Support Intervention for Suicidal Adolescents, acronym: SWEEP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2026-04, completionDateStruct date: 2026-04, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Albert Einstein College of Medicine, class: OTHER, collaborators name: American Foundation for Suicide Prevention, collaborators name: Yeshiva University, descriptionModule briefSummary: Suicide risk has increased among youth in underserved communities, where access to mental healthcare is limited. To address this need, the investigator team plans to evaluate the preliminary efficacy of a brief, low-cost, culturally responsive digital intervention for ethnically diverse youth at risk for suicide in The Bronx, NY. In collaboration with community stakeholders, suicide recovery narratives, featuring adolescents' experiences related to recovery from suicidal thoughts will be developed. A smartphone ecological momentary assessment app will be used to evaluate whether a curriculum of these narratives provides anti-suicidal benefits to at-risk adolescents., conditionsModule conditions: Suicide, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The first 6 participants will serve as a brief pilot to validate outcomes and the acceptability of the intervention. The study team may make slight changes to the intervention (e.g., time of day the suicide recovery narratives are administered, or which narratives are presented) before recruiting the remaining 40 participants., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: Supporting Wellbeing with Everyday Experiences of Peers (SWEEP), outcomesModule primaryOutcomes measure: Suicidal Thoughts, secondaryOutcomes measure: Suicidal Urge Resistance, secondaryOutcomes measure: Social Connectedness, secondaryOutcomes measure: Optimism, secondaryOutcomes measure: Social Support, secondaryOutcomes measure: Intervention Acceptability, otherOutcomes measure: Emotions, otherOutcomes measure: Treatment Readiness, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349902, orgStudyIdInfo id: Pro00077561, briefTitle: Re-link HCV in Substance-Use Telemedicine Program, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: trueNorth Medical Centres, class: OTHER, collaborators name: Gilead Sciences, descriptionModule briefSummary: This is an observational, retrospective \& prospective cohort study. The retrospective element of the study is a chart review to identify people with diagnosed but untreated HCV and re-link them to care. The observational prospective cohort element of the study will examine the HCV linkage to care, treatment initiation, treatment completion \& cure rates of these HCV clients achieved through this chart review and re-linking approach., conditionsModule conditions: Hepatitis C, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 5000, type: ESTIMATED, armsInterventionsModule interventions name: Re-Link, outcomesModule primaryOutcomes measure: number of patients identified as having diagnosed but untreated HCV, primaryOutcomes measure: percentage of patients identified as having diagnosed but untreated HCV that are re-linked to HCV care, secondaryOutcomes measure: treatment initiation rates, secondaryOutcomes measure: treatment completion dates, secondaryOutcomes measure: cure rates, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: trueNorth Medical Centre, status: RECRUITING, city: Toronto, state: Ontario, zip: M5B 2A5, country: Canada, contacts name: Hannah O'Reilly, BSc, role: CONTACT, phone: 8888783563, phoneExt: 6452, email: hannah.oreilly@truenorthmedical.com, contacts role: CONTACT, phoneExt: Cavacuiti, email: drccavacuiti@truenorthmedical.com, contacts name: Chris Cavacuiti, BA, MD, MHSc, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False
protocolSection identificationModule nctId: NCT06349889, orgStudyIdInfo id: MA-NPC-II-004, briefTitle: Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-05-01, completionDateStruct date: 2028-05-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, collaborators name: Nanfang Hospital, Southern Medical University, collaborators name: West China Hospital, descriptionModule briefSummary: This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC)., conditionsModule conditions: Nasopharyngeal Carcinoma, conditions: Nasopharyngeal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Adebrelimab, outcomesModule primaryOutcomes measure: Failure-free survival (FFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Distant metastasis-free survival (DMFS), secondaryOutcomes measure: Locoregional recurrence-free survival (LRRFS), secondaryOutcomes measure: Adverse events (AEs) and serious adverse events (SAEs), secondaryOutcomes measure: Quality of life (QoL), secondaryOutcomes measure: Failure-free survival (FFS) within different subgroups, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nanfang Hospital, Southern Medical University, city: Guangzhou, state: Guangdong, zip: 510000, country: China, contacts name: Jian Guan, M.D., role: CONTACT, geoPoint lat: 23.11667, lon: 113.25, locations facility: West China Hospital, Sichuan University, city: Chengdu, state: Sichuan, zip: 610000, country: China, contacts name: Lei Liu, M.D., role: CONTACT, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06349876, orgStudyIdInfo id: SUEZ MED - IRB Approval NO: 6, briefTitle: Cholecystectomy in Patients With Silent Common Bile Duct Stones, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-15, primaryCompletionDateStruct date: 2023-07-15, completionDateStruct date: 2024-01-15, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Suez University, class: OTHER, descriptionModule briefSummary: Aim of this study is to evaluate the efficacy of performing only cholecystectomy in patients with asymptomatic common bile duct stones without dealing with common bile duct stones, conditionsModule conditions: Performing Cholecystectomy in Patients With Chronic Calcular Choleycystits, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: laparoscopic cholecystectomy, outcomesModule primaryOutcomes measure: number of patients developed jaundice post cholecystectomy, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Qeft Teatching Hospital, city: Qinā, country: Egypt, geoPoint lat: 26.16418, lon: 32.72671, locations facility: Qena Faculty of Medicine, city: Qinā, country: Egypt, geoPoint lat: 26.16418, lon: 32.72671, locations facility: Suez Faculty of Medicine, city: Suez, zip: 43221, country: Egypt, geoPoint lat: 29.97371, lon: 32.52627, hasResults: False
protocolSection identificationModule nctId: NCT06349863, orgStudyIdInfo id: W23.225, briefTitle: Dutch CHolEcystitis Snapshot Study, acronym: Dutch-CHESS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: St. Antonius Hospital, class: OTHER, collaborators name: St. Antonius Onderzoeksfonds, collaborators name: Dutch Snapshot Research Group, collaborators name: Nederlandse Leverpatientenvereniging, descriptionModule briefSummary: Background: Cholecystitis is treated by in various types of hospitals by different specialists, and treatment strategy is influenced by logistical and medical reasons and personal preference. This may significantly impact hospital stay and other outcomes.Purpose: To determine the variation in treatment of cholecystitis in the Netherlands and its impact on outcome.Methods: Nation-wide cohort study of all patients diagnosed and treated for cholecystitis during a 6 month period. The primary outcome will be the proportion of patients with an acute cholecystitis in which the guideline is followed. This group will be compared to those in which the guideline is not followed, focussing on total hospital stay and complications. Secondary aims are to determine: factors related to guideline compliance; the best method of cystic duct closure; the best treatment strategy for a \>7-day existing cholecystitis; factors predictive for concomitant common bile duct stones; strategies following gallbladder drainage. Multivariable analysis and propensity score matching will be used when appropriate for the etiological study aims. The TRIPOD guideline for prediction modelling will be used for the predictive study aims. Hospitals will receive their own results, set out against the national average and best practices, thereafter subsequent changes in hospital practice will be recorded.Conclusion: This study will determine the variation in treatment of cholecystitis in the Netherlands and its impact on clinical outcome. Its results will serve as an important incentive to create optimal, uniform cholecystitis treatment in the Netherlands., conditionsModule conditions: Cholecystitis, conditions: Cholecystitis; Gallstone, conditions: Cholecystitis; Choledocholithiasis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 3000, type: ESTIMATED, outcomesModule primaryOutcomes measure: Total hospital stay, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 120 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349850, orgStudyIdInfo id: Soh-Med-24-03-06MS, briefTitle: Predictive Value of Serum Uric Acid to High Density Lipoprotein Cholesterol Ratio for Diabetic Kidney Injury in Type 2 Diabetes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: An prospective observetional study to asses the predictive value of serum uric acid to high density lipoprotein cholesterol ratio for diabetic kidney injury in type 2 diabetes, conditionsModule conditions: Diabetic Kidney Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: serum uric acid level to plasma HDL-c level ratio (UHR), outcomesModule primaryOutcomes measure: Uric acid to HDL-c ratio (UHR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349837, orgStudyIdInfo id: ECLIPSE-02, briefTitle: Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Sichuan University, class: OTHER, descriptionModule briefSummary: This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with bulky tumors who have failed standard therapy. At least 9 participants will be enrolled in this study., conditionsModule conditions: Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 9, type: ESTIMATED, armsInterventionsModule interventions name: Tislelizumab, interventions name: Low Dose Radiotherapy, interventions name: Stereotactic Ablative Radiotherapy, outcomesModule primaryOutcomes measure: Dose Limiting Toxicities, secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Progression Free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349824, orgStudyIdInfo id: 004AEstb/EC/01/2022, briefTitle: Dextrose, Steroid, PRP: Choosing the Right Injection for CRS Relief; a RCT, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-10-10, primaryCompletionDateStruct date: 2024-03-30, completionDateStruct date: 2024-03-30, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Sheikh Zayed Medical College, class: OTHER_GOV, descriptionModule briefSummary: USG guided injections to relieve carpal tunnel syndrome with dextrose water or steroid or PRP, conditionsModule conditions: Carpal Tunnel Syndrome, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: injection Dextrose water, interventions name: USG machine, outcomesModule primaryOutcomes measure: VAS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sheikh Zayed Medical College, city: Rahim yar khan, state: Punjab, zip: 64200, country: Pakistan, geoPoint lat: 28.41987, lon: 70.30345, hasResults: False
protocolSection identificationModule nctId: NCT06349811, orgStudyIdInfo id: BL-M05D1-101, briefTitle: A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Sichuan Baili Pharmaceutical Co., Ltd., class: INDUSTRY, collaborators name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., descriptionModule briefSummary: This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in patients with locally advanced or metastatic solid tumors., conditionsModule conditions: Locally Advanced or Metastatic Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: BL-M05D1, outcomesModule primaryOutcomes measure: Phase Ia: Dose limiting toxicity (DLT), primaryOutcomes measure: Phase Ia: Maximum tolerated dose (MTD), primaryOutcomes measure: Phase Ib: Recommended Phase II Dose (RP2D), secondaryOutcomes measure: Treatment-Emergent Adverse Event (TEAE), secondaryOutcomes measure: Cmax, secondaryOutcomes measure: Tmax, secondaryOutcomes measure: T1/2, secondaryOutcomes measure: AUC0-t, secondaryOutcomes measure: CL (Clearance), secondaryOutcomes measure: Ctrough, secondaryOutcomes measure: ADA (anti-drug antibody), secondaryOutcomes measure: Phase Ib: Objective Response Rate (ORR), secondaryOutcomes measure: Phase Ib: Disease Control Rate (DCR), secondaryOutcomes measure: Phase Ib: Duration of Response (DOR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Cancer Hospital, city: Beijing, state: Beijing, country: China, contacts name: Lin Shen, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06349785, orgStudyIdInfo id: P.T.REC/012/003858, briefTitle: Manual Hyperinflation and Physical Therapy Program on Lung Recruitment Mechanically Ventilated Pediatric Patients, acronym: MHI, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-12-20, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-29, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: New Ismailia National University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to investigate the immediate combined effects of Manual Hyperinflation and standard Physical therapy program on lung recruitment and secretion mass in mechanically ventilated pediatric patients aged between 10-15 years 'old, conditionsModule conditions: Mechanical Ventilation Complication, conditions: Physical Disability, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized controlled trial, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: using sealed envelopes,, whoMasked: PARTICIPANT, enrollmentInfo count: 32, type: ACTUAL, armsInterventionsModule interventions name: rehabilitation of mechanically ventilated patients, interventions name: supportive care, outcomesModule primaryOutcomes measure: change the respiratory functions, primaryOutcomes measure: change the respiratory mechanics, primaryOutcomes measure: change the bronchospasm, primaryOutcomes measure: change the amount of ventilation, secondaryOutcomes measure: decreasing the amount of secretions, secondaryOutcomes measure: weaning from mechanical ventilator, eligibilityModule sex: ALL, minimumAge: 10 Years, maximumAge: 15 Years, stdAges: CHILD, contactsLocationsModule locations facility: College of Medicine, city: Ismailia, zip: 41522, country: Egypt, geoPoint lat: 30.60427, lon: 32.27225, hasResults: False